Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Preferred Stock Liabilities (2023 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Preferred Stock Liabilities over the past 3 years, most recently at $46.1 million for Q2 2025.

  • Quarterly results put Preferred Stock Liabilities at $46.1 million for Q2 2025, up 8.24% from a year ago — trailing twelve months through May 2025 was $46.1 million (up 8.24% YoY), and the annual figure for FY2025 was $46.1 million, up 8.24%.
  • Preferred Stock Liabilities for Q2 2025 was $46.1 million at Lifecore Biomedical, Inc. \De\, up from $45.2 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for LFCR hit a ceiling of $46.1 million in Q2 2025 and a floor of $38.5 million in Q1 2023.
  • Median Preferred Stock Liabilities over the past 3 years was $42.2 million (2024), compared with a mean of $42.2 million.
  • Biggest five-year swings in Preferred Stock Liabilities: rose 8.34% in 2024 and later increased 8.24% in 2025.
  • Lifecore Biomedical, Inc. \De\'s Preferred Stock Liabilities stood at $40.9 million in 2023, then rose by 8.28% to $44.3 million in 2024, then grew by 4.03% to $46.1 million in 2025.
  • The last three reported values for Preferred Stock Liabilities were $46.1 million (Q2 2025), $45.2 million (Q1 2025), and $44.3 million (Q4 2024) per Business Quant data.